Skip to content

Ansa Biotechnologies Closes Oversubscribed $68 Million Series A Financing to Power the Next Era of DNA-Enabled Industries

  • Published
  • Ansa’s next-generation enzymatic DNA synthesis technology will dramatically accelerate innovation across every industry enabled by synthetic DNA from biologic drugs to biomanufacturing, and DNA-based data storage.
  • Funding will advance next-generation technology platform, expand R&D and manufacturing facilities, grow multidisciplinary team, and launch DNA synthesis service.
  • Ansa is solving current industry bottlenecks associated with synthesizing complex DNA sequences that are difficult to obtain from existing DNA synthesis providers.

View the press release.